These two authors contributed equally to this work. Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in California than in Spaniards (SP). This was assumed to be related to the low CYP2C9*2 and *3 allele frequencies in Orientals. This study was therefore aimed at analyzing whether there were also differences in CYP2C9 allele frequencies between Mexican-Tepehuanos (MT) and Mexican-Mestizos (MM) living in northwestern Mexico and SP. The CYP2C9*2 frequency was expected to be lower in the indigenous MT than in the two other groups, and lower in MM than in SP as in our earlier study. CYP2C9 genotypes and allele frequencies of two populations of healthy volunteers, MT (n ¼ 99) and MM (n ¼ 102), were compared with a population of SP (n ¼ 327). The data were also compared with our previously published population of Mestizo-Mexican-Americans (MA). The CYP2C9 genotypes among the studied populations were in equilibrium. The frequencies of CYP2C9*2 were 0.01, 0.07, 0.08, and 0.16 for MT, MM, MA, and SP subjects, respectively. In agreement with our hypothesis, CYP2C9*2 was significantly lower in the Mexican populations than in the SP (Po0.05), and among Mexicans in the MT than in the MM and MA groups (Po0.05), which presented similar frequencies. Moreover, the frequency of CYP2C9*3 was found to be lower (Po0.05) in MM (0.015) and MT (0.015) than in MA (0.06) and SP (0.08). Finally, the CYP2C9*6 allele was present just in one MM subject, and CYP2C9*4 and *5 were not found in the studied populations. Therefore, these findings add further evidence about CYP2C9 genetic diversity within Hispanic populations with regard to their ancestry. Considering that CYP2C9*2 and CYP2C9*3 alleles have altered catalytic activities relative to CYP2C9*1, the present data suggest the need for pharmacogenetic studies to optimize drug dosages in different populations.
Introduction
Interethnic differences in cytochrome P450 (CYP) polymorphism might be responsible, at least in part, for the variations in drug disposition between ethnic groups. The genetic polymorphism of the CYP enzymes is one of the major determinants of interindividual variability of pharmacokinetics and drug response. 1 The CYP2C subfamily is large and complex. 2 CYP2C9 metabolizes therapeutically important drugs including several worldwide prescribed anti-hypertensive, anti-diabetic, nonsteroidal anti-inflammatory drugs, and narrow therapeutic index drugs (that is warfarin and phenytoin). [3] [4] [5] Therefore, CYP2C9 interindividual variability can result in either drug toxicity (for example warfarin-induced bleeding complications) or therapeutic failure. 6, 7 The human gene coding for the CYP2C9 protein has been mapped to chromosome 10q24.2, and is 455 kb in length. 4 The most common allele, and considered the wild type, is denoted CYP2C9*1. Some CYP2C9 variants codify proteins with decreased activity (CYP2C9*2, *3, *4, *5), whereas allele CYP2C9*6-a base pair deletion at position 818, which yields a premature stop codon-encodes a truncated inactive protein. 8 Despite Hispanics constituting one of the largest groups in the world, including in the United States, where they are the second largest population group, there has been as yet a paucity of pharmacogenetic studies on this group. In particular, those of a Mexican origin represent the largest fraction (65%) of the USA's Hispanic population. The ethnic background of this group mostly derives from an admixture over the past five centuries of local Ancient Amerindians and Europeans from Spain, leading to 480% of Mexican 'Mestizos' today, with other indigenous groups less intermixed. Therefore, we thought it would be informative to compare the CYP2C9 allele frequencies of two Mexican populations of different ancestral components (Mestizo and Amerindian) living in Durango (a northern state of Mexico) with Spaniards (SP). In addition, these data will be compared with the previously studied population of Mexican-Mestizos living in California, which presented a lower frequency of CYP2C9*2 than SP. 9 As prior studies had reported a lower frequency of CYP2C9*2 and *3 alleles in Oriental populations than in Caucasians (Figure 1 ), we thought that the low CYP2C9*2 frequency in this population of MexicanAmericans might be due to the Oriental ancestry present in Amerindians. Therefore, the aim of this study was to analyze the differences in the frequency of CYP2C9 genetic polymorphisms between two Mexican populations, Amerindian Tepehuanos (MT) and Mestizos (MM), and a Caucasian population of SP. In addition, all these data were also compared with a previously studied population of MexicanAmerican Mestizos (MA).
Materials and methods
Subjects and study protocol Two populations of Mexicans living in the northern states, one group of 102 subjects classified as Mestizos from Durango and a group of 99 Amerindian Tepehuanos previously described elsewhere 10 participated in this study. They were defined as people with at least three grandparents born in Mexico. The MT subjects were inhabitants of the Guajolota Community (Municipality of Mezquital) and the MM subjects were residents of Nuevo Ideal (Municipality of Nuevo Ideal). In addition, a total population of 327 White Europeans living in Extremadura (Spain), extended from the previously published population of 102 SP that were compared with a group of 98 unrelated healthy MA individuals living in Los Angeles, California, 9 were included in this study for comparison purposes concerning CYP2C9.
All subjects were informed about the aims of the study and gave their consent to participate. The earlier study was approved by the UCLA Human Subjects Protection Committee and by the Ethical Committee of Extremadura University Hospital (Spain), and this study by the latter Ethical Committee and by the Ethical and Research Committee of the Durango General Hospital of the Mexican Health Ministry.
CYP2C9 genotyping
Venous blood (10 ml) was obtained from each volunteer. Blood samples were collected in EDTA tubes, and genomic DNA was isolated using the Gentrapuregen kit (Indianapolis, IN, USA). Genotyping for CYP2C9*2, *3, and *6 allelic variants was performed using fluorescence-based allelespecific TaqMan allelic discrimination assay, and CYP2C9*4 and *5 alleles by polymerase chain reaction with the conditions, primers, and restriction enzymes described elsewhere. 9 For each CYP2C9 single-nucleotide polymorphism for CYP2C9*2, *3, and *6 allele identification, a predeveloped TaqMan assay reagent kit, containing one pair of polymerase chain reaction primers and one pair of fluorescent TaqMan probes was purchased from Applied Biosystems (Forster City, CA, USA). Polymerase chain reaction amplification for all single-nucleotide polymorphisms was performed in 20 ml reactions with 30 ng template DNA, 1 Â Taqman Universal Master Mix (Applied Biosystems), 1 Â each primer and probe assay, and water. Thermal cycling was initiated with a first denaturation step of 10 min at 95 1C, followed by 40 cycles of denaturation at 92 1C for 15 s, and annealing at 60 1C for 1 min. The allele detection process was performed for 1 min at 60 1C on a Fast 7300 Real-Time System (Applied Biosystems) to determine the allelic discrimination.
Statistics
The CYP2C9 allele frequencies were compared by using Fisher's exact test. Hardy-Weinberg equilibrium was determined by comparing the genotype frequencies with the expected values using a contingency table w 2 statistic with Yates's correction. A P-value o0.05 was regarded as statistically significant in all cases. Statistical analyses were performed using GraphPad QuickCalcs (GraphPad Software, Inc., San Diego, CA).
Results
The CYP2C9 genotype frequencies for the healthy volunteer populations studied (Table 1) corresponded to those predicted by the Hardy-Weinberg law. Among them, only one individual (MM) was found to carry the mutated allele CYP2C9*6. No subject homozygous for CYP2C9*2 or CYP2C9*3 alleles was detected in any Mexican population. Figure 1 . The frequencies of CYP2C9*2 were 0.01, 0.07, 0.08, and 0.16 for MT, MM, MA, and SP subjects, respectively (Table 2). As described earlier for MA vs SP, the frequency of CYP2C9*2 was also found to be lower (Po0.05) among the studied MT and MM groups living in Mexico than in this extended population of SP. Furthermore, among Mexicans, the CYP2C9*2 frequency was lower in the MT than in the two Mestizo populations (MM and MA), which presented very similar frequencies (Table 2 ).
CYP2C9 among Mexicans
In addition, the SP population studied here presented similar CYP2C9 allele frequencies to those previously reported in a recent publication of frequencies found in northern regions of South Europeans. 11 Furthermore, the frequency of CYP2C9*3 was lower (Po0.05) in MT (0.015) and MM (0.015) than in MA (0.06) and SP (0.08).
As previously found in MA, 9 CYP2C9*4 and *5 were found in none of the studied subjects. However, the CYP2C9*6 allele was found just in one MM subject.
Discussion
Earlier, we had described a lower frequency of CYP2C9*2 among Mexican Americans compared with SP from Extremadura. 9 As low CYP2C9*2 and *3 allele frequencies had already been reported in Orientals vs Caucasians at that time, we explained the CYP2C9*2 differences between MA and SP as reflecting Mexicans' Oriental ancestry. The present findings confirm a lower CYP2C9*2 allele frequency in Mexican-Amerindians (MT) and another population of Mexican Mestizos living in Mexico (MM) than in an extended population of SP from Extremadura. Indeed, there were also differences between Mexican populations, whereas the Mestizos living in Mexico or in the US presented almost the same CYP2C9*2 frequencies (0.07; 0.08), both higher than that found in MT (0.01). These results seem to lend further support to the negative correlation between the CYP2C9*2 frequency and the degree of Oriental ancestry (Figure 1) . Similarly, the lower frequencies of CYP2C9*3 allele among these populations of Mexicans living in Mexico (MM and MT) than among Caucasians and the previously studied MA also appear to be evidence for the Oriental genetic background (Figure 1 ). In a study of 100 Mexican subjects, 12 the frequencies of CYP2C9*2 and *3 alleles were found to be 0.1 and 0.03, respectively, which are not significantly different from the Mexican Mestizo populations (MM and MA) reported here. Moreover, the CYP2C9*2 12 was significantly higher (Po0.05) than in MT. The Mexican population is a complex admixture of ethnic groups that combine the genetic background of several Amerindian groups derived from a migration of Asians to Beringia, with White Europeans coming from Europe in general and from Spain and specific areas such as Extremadura in particular. In addition, the present Spanish population from Extremadura appeared very representative, as it was found to be very similar in CYP2C9 allele frequencies to previously published data of White Europeans. 11, 13, 14 Clinical implications for patients carrying the low activity alleles CYP2C9*2 and CYP2C9*3 have been reported. Patients who are CYP2C9 'slow metabolizers', mostly *3/*3 carriers, and are under treatment with some narrow therapeutic index drugs (warfarin, acenocoumarol, glipizide, and phenytoin) may be at risk of severe drug toxicity. 6, 7 Moreover, 'slow metabolizers' may have therapeutic failure when treated with a prodrug that requires CYP2C9-mediated bioactivation to produce its drug effects (for example losartan, cyclophosphamide). 15, 16 Thus, the present results suggest that the Mexican populations studied might have lower genetic risk of adverse drug reaction than Caucasian populations for drugs metabolized by CYP2C9.
In sum, the frequency of the CYP2C9*2 allele was higher in the Spanish population studied than in MA, MM from Durango, and MT, confirming the results of our earlier study and suggesting a relationship with Oriental ancestry. However, the CYP2C9*3 allele frequency was lower than that previously reported among White Europeans and MA, but similar to that of African-Americans (Figure 1) . Finally, to the best of our knowledge, the present data and our earlier findings also allow us to hypothesize that there is a lack or very low presence of CYP2C9*4,*5, and *6 allelic variants among Hispanics. Therefore, the allelic distribution of the CYP2C9 gene in these three Mexican populations appears compatible with the genomic assembly of the 
